Climb Bio
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
WELLESLEY HILLS, Mass., Sept. 29 -- Climb Bio, Inc., a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced results from a completed nonhuman primate (NHP) study comparing CLYM116 to sibeprenlimab, a first-generation anti-APRIL (anti-A proliferation-inducing ligand) monoclonal antibody.
“We are highly encouraged by the differentiated profile observed with CLYM116, as highlighted in our newly shared nonhuman primate data,” said Aoife Brennan, President and CEO of Climb Bio. “CLYM116 is the only known ‘sweeper’ anti-APRIL monoclonal antibody in development, which we believe could provide a compelling clinical profile in IgAN. In this head-to-head preclinical study, our data have shown improvements in pharmacokinetic and pharmacodynamic measures – namely a longer half-life and deeper and more durable IgA reductions – as compared to sibeprenlimab, a first-generation anti-APRIL monoclonal antibody. These data highlight the potential for CLYM116 to provide a differentiated activity profile with less frequent dosing. Notably, the updated KDIGO treatment guideline published earlier this month highlights the need for more active management of IgAN, and we believe that the adoption of these approaches could expand the CLYM116 market opportunity. We are excited to advance CLYM116 development and look forward to initiation of a Phase 1 trial later this year, with initial data anticipated mid-year 2026.”
CLYM116 Data & Event Highlights
New CLYM116 NHP data demonstrate improvement versus sibeprenlimab (first-generation anti-APRIL monoclonal antibody). Subcutaneous formulation demonstrated high bioavailability (~85%), with a favorable tolerability profile. Prolonged exposure observed compared to sibeprenlimab, with a ~2-3 times longer half-life across doses. Deeper and more prolonged IgA reduction observed compared to sibeprenlimab after a single subcutaneous administration at equivalent doses (6 mg/kg), with >70% maximal reduction in IgA observed with CLYM116. Additional in vivo studies in mice showed enhanced APRIL elimination and antibody recycling relative to sibeprenlimab
